Pfizer celebrates accelerated win for potential multiple myeloma blockbuster

Pfiz­er has se­cured an ac­cel­er­at­ed ap­proval for El­rex­fio, a po­ten­tial mul­ti­ple myelo­ma block­buster that Pfiz­er ex­pects could be­come a “multi­bil­lion-dol­lar fran­chise.”

El­rex­fio, al­so known as el­ranatam­ab, will be avail­able for re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma pa­tients who’ve had at least four pri­or ther­a­pies, in­clud­ing a pro­tea­some in­hibitor, an im­munomod­u­la­to­ry agent and an an­ti-CD38 mon­o­clon­al an­ti­body, Pfiz­er an­nounced Mon­day. The drug tar­gets BC­MA on myelo­ma cells and CD3 on T cells, prompt­ing the T cells to at­tack the myelo­ma cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.